Epicrispr has added a veteran biotech deal-maker to its board as its lead epigenetic therapy for a rare muscle disease moves closer to late-stage testing.
Enoch Kariuki, a pharmacist-turned-biotech executive who has steered more than $10 billion in life sciences financings and mergers, has been named to the board of directors of Epicrispr Biotechnologies. The San Francisco-based clinical-stage company announced the appointment on October 20, 2026, as it prepares to move its lead epigenetic therapy, EPI-321, toward pivotal development.
The move gives Epicrispr a director whose career has centred on building biotech companies, raising capital and negotiating sales to large drugmakers. That combination tends to matter most when a young company is weighing how to fund expensive late-stage trials and grow its pipeline.
Enoch Kariuki’s Record: More Than $10 Billion in Biotech Financings and Deals
According to the company, Dr. Kariuki has led more than $10 billion in strategic financings and mergers and acquisitions across the life sciences sector. His experience spans company building, corporate strategy, capital markets and business development.
He currently serves as President of Endeavor BioMedicines, where he oversees corporate strategy and operations. Several of the companies he has helped lead or advise were later acquired by some of the best-known names in the pharmaceutical industry.
From Synthorx to Endeavor BioMedicines: A Career Built Around Acquisitions
A recurring theme in Dr. Kariuki’s résumé is the successful sale of the companies he worked for. The table below summarises the executive and finance roles disclosed in the announcement.
| Company | Role | Outcome noted |
|---|---|---|
| Endeavor BioMedicines | President (current) | Leads corporate strategy and operations |
| Lengo Therapeutics | Chief Executive Officer | Acquired by Blueprint Medicines |
| VelosBio | Chief Financial Officer | Acquired by Merck |
| Synthorx | Senior Vice President, Corporate Development | Led its initial public offering; key role in its acquisition by Sanofi |
| H.I.G. Capital, Leerink Partners, UBS Investment Bank | Investment and advisory roles | Not specified |
His path into the industry began on the scientific side. He holds a Doctor of Pharmacy degree from Texas Southern University and an MBA from the Tuck School of Business at Dartmouth College. He also completed a postdoctoral fellowship in R&D strategy and analytics at Bristol Myers Squibb.
Audit Committee Chair at Zentalis and Pheon Therapeutics
The Epicrispr seat is not Dr. Kariuki’s only board role. He currently sits on the boards of Zentalis Pharmaceuticals and Pheon Therapeutics, and chairs the audit committee at both companies.
He has also served on the boards of Imago Biosciences and ProfoundBio. Both were later acquired, Imago by Merck and ProfoundBio by Genmab.
Audit committee chairs carry particular weight in corporate governance. They oversee financial reporting, internal controls and the relationship with outside auditors. Holding that role at two companies at once signals that boards view him as a financially rigorous director, not only a deal-maker.
EPI-321 and the Push Toward Pivotal Development in FSHD
Epicrispr’s lead program, EPI-321, is in clinical trials for facioscapulohumeral muscular dystrophy, commonly shortened to FSHD. The company says it intends to advance the therapy toward pivotal development, the stage of testing typically designed to produce the evidence regulators review when deciding whether to approve a treatment.
General context: FSHD is an inherited muscle disorder. As its name indicates, it typically affects muscles of the face, the area around the shoulder blades and the upper arms, and it can progress over time. Patient groups have long described it as a condition with significant unmet medical need.
In his statement, Dr. Kariuki said early clinical data were “compelling” and pointed to the potential of the company’s platform to address diseases with significant unmet need. He described Epicrispr’s work on EPI-321, together with its broader ambitions for programmable epigenetic medicines, as an opportunity to establish an important new type of therapy.
The announcement did not disclose specific trial results, timelines for a pivotal study, or the size of any planned financing. Readers should treat EPI-321 as an investigational therapy that has not been approved by regulators.
How Epicrispr’s GEMS Platform Approaches Epigenetic Medicine
Epicrispr describes itself as a biotechnology company pioneering gene-modulating therapies, starting with neuromuscular diseases. Its core technology is a proprietary system it calls the Gene Expression Modulation System, or GEMS.
The company says GEMS is designed to adjust how strongly genes are expressed in a precise and durable way. Rather than cutting or rewriting DNA, epigenetic approaches generally aim to change whether, and how much, a gene is switched on.
- Lead focus: Neuromuscular diseases, beginning with FSHD.
- Stated goal: First-in-class treatments for conditions that currently have no effective therapy.
- Pipeline: Additional gene-modulating programs are in development, though the company did not name them in this announcement.
What Amber Salzman Expects From the New Director
Chief Executive Officer Amber Salzman, Ph.D., framed the appointment around the company’s next phase. She called Dr. Kariuki an accomplished leader with a record of building and scaling companies, guiding programs through major clinical and regulatory milestones, and completing strategic transactions.
Dr. Salzman said his operational, strategic and financial expertise would be valuable as Epicrispr moves EPI-321 toward pivotal development and expands its pipeline of epigenetic medicines. She described the timing as an important stage in the company’s growth.
For his part, Dr. Kariuki said he looked forward to working with Dr. Salzman, the leadership team and fellow directors to advance the company’s strategic priorities and bring new therapies to patients.
Why a Deal-Maker on the Board Matters for a Clinical-Stage Biotech
Board appointments at small drug developers can look routine, but they often hint at where a company is heading. Adding a director best known for financings, an IPO and multiple acquisitions suggests Epicrispr is thinking carefully about how to pay for late-stage development and what strategic options may follow.
General industry context: Pivotal trials are usually the most expensive phase of drug development, and clinical-stage companies frequently need fresh capital or partnerships to complete them. Directors with capital markets and M&A experience can help a board evaluate funding rounds, licensing offers or potential sale approaches. Nothing in the announcement indicates that any such transaction is planned.
The pattern is familiar to Canadian readers who follow the country’s life sciences and technology sectors. Domestic biotech firms, like their U.S. peers, often recruit directors with financing and audit expertise as programs mature, since investors and regulators look closely at governance once a company is spending heavily on late-stage research. Epicrispr itself did not reference Canada or any Canadian operations in its announcement.
For now, the appointment is a signal of intent rather than a milestone in itself. The more consequential news for patients and investors will be the clinical data and pivotal-trial plans for EPI-321, which the company has yet to detail publicly.
This article reports on a corporate announcement and does not constitute medical or investment advice. EPI-321 remains an investigational therapy.
